In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)
- 1.3k Downloads
There is growing evidence that memantine, a noncompetitive N-methyl-d-aspartate receptor antagonist, may be applied as an add-on in treating patients suffering from obsessive–compulsive disorders (OCD). The aim of the present study was therefore to assess the effect of adjuvant memantine in a double-blind, randomized, and placebo-controlled study of the treatment of patients suffering from OCD.
A total of 40 inpatients (32 females (80 %); mean age = 31.25 years) suffering from OCD were randomly assigned to a treatment (administration of memantine) or a control group (placebo). Treatment lasted for 12 consecutive weeks. All patients were treated with selective serotonin re-uptake inhibitors or clomipramine. Patients completed the Yale–Brown Obsessive Compulsive Scale four times. Experts’ ratings consisted in clinical global impression (clinical global impressions (CGI), illness severity and illness improvement; two to three times). Liver enzymes SGOT and SGPT were also assessed (twice).
Of the 40 inpatients approached, 29 completed the 12 consecutive weeks of the study. Of the 11 dropouts, 6 were in the target group and five in the control group. Symptoms significantly decreased across the period of the study, but particularly in the treatment compared with the control group (significant time × group interaction). Illness severity (CGI severity) also significantly decreased over time but more so in the treatment than in the control group (significant time × group interaction). Illness improvements (CGI improvements) were not significant.
The pattern of results from the present double-blind, randomized, and placebo-controlled study for the treatment of patients suffering from OCD suggests that adjuvant memantine does significantly and favorably impact on OCD.
KeywordsObsessive–compulsive disorder Memantine SSRIs Double-blind trial Placebo Y-BOCS
Conflict of interest
All authors declare no conflicts of interest; the entire study was performed without external funding
- American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
- Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Lawrence Erlbaum Associates, HillsdaleGoogle Scholar
- Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X (2005) Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive–compulsive disorder. Am J Psychiatry 162:151–161PubMedCrossRefGoogle Scholar
- Guy W (1976) ECDEU assessment for psychopharmacology, revised edition. NIMH Publication, RockvilleGoogle Scholar
- Hanna GL, Himle JA, Curtis GC, Gillespie BW (2005) A family study of obsessive–compulsive disorder with pediatric probands. Am J Med Genet B Neuropsychiatr Genet 134:13–19Google Scholar
- Joint Formulary Committee (2004) British National Formulary (BNF), 47th edn. British Medical Association and the Royal Pharmaceutical Society of Great Britain, LondonGoogle Scholar
- Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ (2004) Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43:1146–1153PubMedCrossRefGoogle Scholar
- Starck G, Ljungberg M, Nilsson M, Jönsson L, Lundberg S, Ivarsson T, Ribbelin S, Ekholm S, Carlsson A, Forssell-Aronsson E, Carlsson ML (2008) A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm 115:1051–1062PubMedCrossRefGoogle Scholar
- Swedo SE, Snider LA (2004) The neurobiology and treatment of obsessive compulsive disorder. In: Nestler EJ, Charney DS (eds) Neurobiology of mental illness. Oxford University Press, New York, pp 628–638Google Scholar